These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 32217661)

  • 1. ROS1-rearranged lung adenocarcinoma with peritoneal carcinomatosis on initial presentation.
    Kazakova V; Alarcon Velasco SV; Perepletchikov A; Lathan CS
    BMJ Case Rep; 2020 Mar; 13(3):. PubMed ID: 32217661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
    Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
    Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
    Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
    Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a Novel RBPMS-ROS1 Fusion in an Adolescent Patient With Microsatellite-instable Advanced Lung Adenocarcinoma Sensitive to Crizotinib: A Case Report.
    Zhang Y; Yu M; Yuan M; Chen R; Huang MJ
    Clin Lung Cancer; 2020 Mar; 21(2):e78-e83. PubMed ID: 31722815
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.
    Morris TA; Khoo C; Solomon BJ
    Drugs; 2019 Aug; 79(12):1277-1286. PubMed ID: 31313100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell transformation in crizotinib-resistant ROS1-rearranged non-small cell lung cancer with retention of ROS1 fusion: A case report.
    Wu CH; Su PL; Hsu CW; Chu CY; Lin CC
    Thorac Cancer; 2021 Nov; 12(22):3068-3071. PubMed ID: 34623764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Crizotinib After Entrectinib Resistance in
    Vaz VR; Gandhi MM; Ricciuti B; Alessi JV; Elkrief A; Ladanyi M; Vanderbilt C; Pecci F; Aldea M; Barrichello A; Saini A; Sholl L; Sands JM; Awad MM
    JCO Precis Oncol; 2024 Oct; 8():e2400394. PubMed ID: 39374479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel ROS1 G2032 K missense mutation mediates lorlatinib resistance in a patient with ROS1-rearranged lung adenocarcinoma but responds to nab-paclitaxel plus pembrolizumab.
    Zhou Y; Jiang W; Zeng L; Mi J; Song L; Lizaso A; Mao X; Yang N; Zhang Y
    Lung Cancer; 2020 May; 143():55-59. PubMed ID: 32208297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of ROS1-rearranged lung adenocarcinoma exhibiting pleural effusion caused by crizotinib.
    Tachi H; Nishino K; Nakaizumi T; Kuramoto K; Shimizu K; Yamamoto Y; Kobayashi K; Ichimura H; Sakata A; Nawa T
    Thorac Cancer; 2020 Jul; 11(7):2063-2066. PubMed ID: 32433811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
    Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
    BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer.
    Pailler E; Auger N; Lindsay CR; Vielh P; Islas-Morris-Hernandez A; Borget I; Ngo-Camus M; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2015 Jul; 26(7):1408-15. PubMed ID: 25846554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib: A case report and literature review.
    Liu L; Wu J; Zhao W; Huang MJ
    Medicine (Baltimore); 2017 May; 96(21):e6979. PubMed ID: 28538401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS).
    Chiari R; Ricciuti B; Landi L; Morelli AM; Delmonte A; Spitaleri G; Cortinovis DL; Lamberti G; Facchinetti F; Pilotto S; Verusio C; Chella A; Bonanno L; Galetta D; Cappuzzo F
    Clin Lung Cancer; 2020 Jan; 21(1):15-20. PubMed ID: 31607443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion.
    Hicks JK; Boyle T; Albacker LA; Madison R; Frampton G; Creelan BC
    J Thorac Oncol; 2018 Aug; 13(8):e148-e150. PubMed ID: 30049378
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of crizotinib as neoadjuvant therapy for non-small cell lung cancers patient with ROS1 rearrangement: A case report.
    Zhao S; Zhu S; Lei X; Xu D; Shi T; Chen Q; Ren F; Chen G; Huang D; Xu S
    Thorac Cancer; 2021 Oct; 12(20):2815-2818. PubMed ID: 34405544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with
    Yue D; Qian J; Chen Z; Zhang B; Chen P; Zhang L; Li J; Zhang H; Wang C
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33558279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.